C12N 2740/13062
By genetic engineering
Official title: by genetic engineering
C12N2740/13062 (By genetic engineering) appears on 22 US grants and 4 published applications in this corpus.
Search patents in C12N- Granted patents
- 22
- Published applications
- 4
- Assignees
- 12
- Inventors
- 30
- Latest grant
- 7 Aug 2007
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 5 | 0 |
| 1998 | 3 | 0 |
| 1999 | 2 | 0 |
| 2000 | 2 | 0 |
| 2001 | 3 | 0 |
| 2002 | 2 | 3 |
| 2003 | 1 | 1 |
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
By publication year. Applications have been published since 2001.
Recent patents
- Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells7 Aug 2007US 7,252,991 B2Cell Genesys, Inc.
- Molecular constructs with a carcinoembryonic antigen (CEA) transcriptional regulatory sequence2 Mar 2004US 6,699,690 B2SmithKline Beecham Corporation
- Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells14 Jan 2003US 6,506,604 B2Cell Genesys, Inc.
- Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy10 Sep 2002US 6,448,390 B1The University of Tennessee Research Corporation
- Molecular constructs containing a carcinoembryonic antigen regulatory sequence8 Jan 2002US 6,337,209 B1
- Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells23 Oct 2003US 2003/0199093 A1Cell Genesys, Inc.
- Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells8 Aug 2002US 2002/0106799 A1Cell Genesys, Inc.
- Molecular constructs with a carcinoembryonic antigen (cea) transcriptional regulatory sequence9 May 2002US 2002/0055482 A1SmithKline Beecham Corporation
- Host-vector system which can be used in gene therapy2 May 2002US 2002/0051763 A1
Most cited
By later US patents
- Recombination resistant retroviral helper cell and products produced thereby142US 5,124,263 AWisconsin Alumni Research Foundation · 1992
- Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells76US 5,686,279 ACell Genesys, Inc. · 1997
- Retroviral vectors expressing cytokines62US 5,635,399 AChiron Corporation · 1997
- Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells59US 5,834,256 ACell Genesys, Inc. · 1998
- VSV G pseusdotyped retroviral vectors54US 5,817,491 AChiron Viagene, Inc. · 1998